SA
LENZ

Sovran Advisors’s LENZ Therapeutics LENZ Stock Holding History

Sovran Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-160,134
Closed -$2.9M – 616
2025
Q4 		$2.9M Buy
160,134
+53,214
+50% +$1.55M 0.25% 108
2025
Q3 		$3.26M Buy
106,920
+66,497
+165% +$2.45M 0.29% 95
2025
Q2 		$1.27M Buy
+40,423
New +$1.1M 0.13% 172

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Sovran Advisors's LENZ Position: Q1 2026 in Review

Sovran Advisors sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 160,134 shares — an estimated $2.9M sold.

Sovran Advisors first reported a position in LENZ in Q2 2025 and held it in 3 quarters. The position peaked at $3.26M in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • Sovran Advisors reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Sovran Advisors sold 160,134 LENZ Therapeutics shares in Q1 2026, an estimated $2.9M.
  • Sovran Advisors first reported a position in LENZ Therapeutics in Q2 2025 and held it in 3 quarters.
  • Sovran Advisors's LENZ Therapeutics position peaked at $3.26M in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Sovran Advisors's 13F filing for Q1 2026, filed 1 May 2026.